en.Wedoany.com Reported - Quotient Sciences has initiated a clinical study to evaluate a novel drug product developed using artificial intelligence (AI). The company noted that this milestone highlights AI's potential in guiding formulation design and accelerating drug development.

This Phase I clinical study, approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), has been launched at Quotient Sciences' UK facility. The study will evaluate the safety and pharmacokinetics of an oral solid dosage form in healthy volunteers.

A key objective of the study is to validate the application of AI in drug product development to accelerate formulation design and drive better drug development decisions. Quotient Sciences believes this is the first reported case of an AI-designed formulation being evaluated in a clinical setting.

Quotient Sciences' AI-driven formulation development program integrates real-time clinical testing, enabling pharmaceutical and biotechnology partners to make faster, more informed decisions early in the development process. This innovative approach enhances clinical predictability and increases the likelihood of successful outcomes.

Andy Lewis, Chief Scientific Officer at Quotient Sciences, stated that the project represents progress in combining advanced machine learning with deep scientific expertise to streamline drug development. Leveraging the company's Translational Pharmaceutics platform, this approach allows clients to make earlier, more confident decisions, ultimately improving the probability of clinical success.

The study utilizes advanced machine learning algorithms from Intrepid Labs to support formulation design and optimization. This AI-driven approach enables rapid exploration of formulation options and more data-driven decisions, helping to optimize the expected clinical performance of the drug product.

This study marks the beginning of a broader strategy at Quotient Sciences focused on integrating AI-driven approaches into formulation development and clinical workflows. The company expects to share further updates and data in the coming months as it continues to advance and expand its AI-driven capabilities.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com